Supplements and Featured Publications
Managing LEMS in SCLC and Oncology Care
Volume: 1
Issue: 1
Targeting c-MET in Advanced Non–Small Cell Lung Cancer
Volume: 1
Issue: 1
Utilizing Antibody-Drug Conjugates and Other Novel Agents in Lung Cancer
Volume: 1
Issue: 1
Utilizing Antibody-Drug Conjugates and Other Novel Agents in Lung Cancer comprises articles and videos on experts discussing therapeutic strategies in the pipeline and on the market for their patients with non–small cell lung cancer.
On the Horizon in NSCLC: Antibody Drug Conjugates
2021 Year in Review: Updates in Biomarker-Driven Lung Cancer
Volume: 1
Issue: 1
The 2021 Year in Review: Updates in Biomarker-Driven Lung Cancer is the digital version of a print publication encompasses some of the biggest data that have read out in bimarker-driven lung cancer in 2021, along with expert insights in article and video format.
Funding From Daiichi Sankyo/Content Developed Independently by OncLive
My Treatment Approach: Lung Cancer Practice Patterns
Volume: 1
Issue: 1
The Evolving Role of Immunotherapy in Metastatic Non–Small Cell Lung Cancer
Volume: 1
Issue: 1
My Treatment Approach: Locally Advanced Lung Cancer
Volume: 1
Issue: 1
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5